Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Hydroxyzine
Drug ID BADD_D01111
Description Hydroxyzine is a first-generation histamine H1-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955,[A189726] and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus.[L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect.[A189753] Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety.[L9677]
Indications and Usage Hydroxyzine is indicated for the symptomatic relief of anxiety and tension associated with psychoneuroses, and as an adjunct in organic disease states in which anxiety is manifested.[L9677] It is also indicated in the treatment of histamine-mediated pruritus and pruritus due to allergic conditions such as chronic urticaria.[L9677] Canadian labeling states that hydroxyzine is also indicated in adults and children as a premedication prior to medical procedures, such as dental surgery.[L9680] It is also used in the control of nausea and vomiting, excluding nausea and vomiting of pregnancy.[L9680]
Marketing Status approved
ATC Code N05BB01
DrugBank ID DB00557
KEGG ID D08054
MeSH ID D006919
PubChem ID 3658
TTD Drug ID D0O6SX
NDC Product Code 65162-577; 65162-575; 65162-671; 52584-007; 0404-9878
UNII 30S50YM8OG
Synonyms Hydroxyzine | 2-(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethanol | Hydroxyzine Dihydrochloride | Vistaril | Hydroxyzine Pamoate | Pamoate, Hydroxyzine | Orgatrax | Durrax | Atarax | Hydroxyzine Hydrochloride
Chemical Information
Molecular Formula C21H27ClN2O2
CAS Registry Number 68-88-2
SMILES C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Headache17.14.01.001--
Hemiparesis17.01.04.0010.000037%
Hepatitis acute09.01.07.0050.000056%-
Hepatocellular injury09.01.07.0080.000037%-
Hyperhidrosis08.01.03.028; 23.02.03.0040.000137%
Hypersensitivity10.01.03.0030.000119%
Hypersomnia17.15.01.001; 19.02.05.0010.000037%
Hypokalaemia14.05.03.0020.000056%
Hyponatraemia14.05.04.0020.000056%
Hypotension24.06.03.002--
Hypoxia22.02.02.0030.000037%
Influenza like illness08.01.03.010--
Injection site bruising08.02.03.042; 12.07.03.042; 23.03.11.015; 24.07.06.0170.000126%-
Injection site erythema08.02.03.001; 12.07.03.001; 23.03.06.0150.000082%-
Injection site induration08.02.03.007; 12.07.03.0070.000145%-
Injection site mass08.02.03.009; 12.07.03.0100.000207%-
Injection site pain08.02.03.010; 12.07.03.0110.000270%-
Injection site reaction08.02.03.014; 12.07.03.0150.000333%
Injection site warmth08.02.03.036; 12.07.03.0360.000082%-
Insomnia17.15.03.002; 19.02.01.002--
Intentional self-injury12.01.08.036; 19.12.01.0020.000074%-
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.0300.000056%-
Joint swelling15.01.02.004---
Lacrimation increased06.08.02.0040.000126%
Lethargy08.01.01.008; 17.02.04.003; 19.04.04.0040.000037%
Long QT syndrome02.03.01.0170.000056%-
Loss of consciousness17.02.04.0040.000130%-
Malaise08.01.01.003--
Migraine17.14.02.001; 24.03.05.003---
Mood altered19.04.02.0070.000126%-
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages